Relmada Therapeutics, Inc. (OTC: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain. The company’s goal is to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, visit the company’s website at www.relmada.com.